MedTrace Logo

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

NCT05118906 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-11-25

No results posted yet for this study

Summary

This pilot study is to assess the efficacy and safety of BP1.4979 15 mg BID in female patients with moderate to severe binge eating disorder (BED), as defined according to DSM-5 guidelines.

Conditions

  • Binge-Eating Disorder

Interventions

DRUG

BP1.4979 active drug

2 tablets 15 mg of BP1.4979 per day

DRUG

Placebo

2 tablets of placebo per day

Sponsors & Collaborators

Principal Investigators

  • Karine Clément, MD, PhD · Nutrition Department, La Pitié Salpêtrière Hospital, Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2025-08-14
Completion
2025-08-21

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05118906 on ClinicalTrials.gov